Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib

• click to rate

  Posted by Two Blokes Jun 30 - Filed in Stock - 5 views
  
  • In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer (“mCRPC”),the six-month radiographic progression free survival (“rPFS”) rate was 66%